A U.S. clinical study suggests that just half a dose of the Novartis AG H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday.
GlaxoSmithKline has won U.S. marketing approval to sell an unadjuvanted H1N1 swine vaccine, allowing it to ship relatively modest amounts of scarce vaccine to the United States next month.
Thursday, 22 Oct 2009 | Posted By:
Mike Huckman | Source: CNBC.com
Swiss drug giant Novartis says it has redeployed 300 workers from other divisions into its vaccines unit to meet what Chairman and CEO Dr. Daniel Vasella calls the "huge demand" for H1N1 shots.
The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.
As flu season goes into high gear in the southern hemisphere, the U.S. Dept. of Homeland Security is preparing for a potential flu outbreak in the United States, according to its top official.
The World Health Organisation warned on Friday against a false sense of security from waning and apparently mild outbreaks of H1N1 flu, saying the worst may not be over.
In what appears to be a bet consumers will stick with discount retailers even after the economy rebounds, Warren Buffett's Berkshire Hathaway increased its Wal-Mart holdings by almost 90 percent during the summer.... Read More